U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H38O6
Molecular Weight 422.5549
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOVASTATIN ACID

SMILES

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC

InChI

InChIKey=QLJODMDSTUBWDW-BXMDZJJMSA-N
InChI=1S/C24H38O6/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28)/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H38O6
Molecular Weight 422.5549
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/show/NCT00580970 | http://medical-dictionary.thefreedictionary.com/lovastatin

Lovastatin acid is an active metabolite of hypolipidemic drug Lovastatin. Lovastatin acid inhibits HMG-CoA reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C). Lovastatin in approved for prevention of cardiovascular events and hypercholesterolemia. Off-label use of lovastatin includes treatmetn of diabetic dyslipidemia, familial dysbetalipoproteinemia, familial combined hyperlipidemia, or nephrotic hyperlipidemia. Lovastatin was tested in clinical trials agains radioation injury during therapy of prostate cancer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.64 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

2002
Palliative
ALTOPREV

Approved Use

1.1 Prevention of Coronary Heart Disease In patients without symptomatic coronary heart disease (CHD), but at high risk, Altoprev® is indicated to reduce the risk of: Myocardial infarction; Unstable angina; Coronary revascularization procedures; Coronary Heart Disease. Altoprev is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels. Hyperlipidemia Altoprev is indicated as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb).

Launch Date

2002
Preventing
MEVACOR

Approved Use

After oral ingestion, lovastatin, which is an inactive lactone, is hydrolyzed to the lovastatin acid. This is a principal metabolite and an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C).

Launch Date

1987
Primary
MEVACOR

Approved Use

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. MEVACOR is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

Launch Date

1987
Secondary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.6 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76.9 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
83 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LOVASTATIN ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Disc. AE: Aspartate aminotransferase increased, Alanine aminotransferase increased...
AEs leading to
discontinuation/dose reduction:
Aspartate aminotransferase increased (grade 2-4, 1.3%)
Alanine aminotransferase increased (grade 2-4, 1.3%)
Gastrointestinal disturbance (0.4%)
Rash (0.27%)
Myalgia (0.13%)
Myopathy (0.27%)
Arthralgia (0.13%)
Insomnia (0.13%)
Weight gain (0.13%)
Sources: Page: p.1082, 1083
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 33.3%)
Aspartate aminotransferase increased (grade 2-3, 33.3%)
Alanine aminotransferase increased (grade 2-3, 33.3%)
Sources: Page: p.527
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
DLT: Creatine phosphokinase increased, Aspartate aminotransferase increased...
Dose limiting toxicities:
Creatine phosphokinase increased (grade 4, 28.6%)
Aspartate aminotransferase increased (grade 3, 14.3%)
Alanine aminotransferase increased (grade 3, 14.3%)
Sources: Page: p.527
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Insomnia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myalgia 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Weight gain 0.13%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Myopathy 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Rash 0.27%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Gastrointestinal disturbance 0.4%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Aspartate aminotransferase increased grade 2-4, 1.3%
Disc. AE
80 mg 1 times / day multiple, oral (max)
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1082, 1083
unhealthy, 50
n = 745
Health Status: unhealthy
Condition: Hypercholesterolemia
Age Group: 50
Sex: M+F
Population Size: 745
Sources: Page: p.1082, 1083
Alanine aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Aspartate aminotransferase increased grade 2-3, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 33.3%
DLT
10 mg/kg 4 times / day multiple, oral (total daily dose)
Highest studied dose
Dose: 10 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 6
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 6
Sources: Page: p.527
Alanine aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Aspartate aminotransferase increased grade 3, 14.3%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
Creatine phosphokinase increased grade 4, 28.6%
DLT
7.5 mg/kg 4 times / day multiple, oral (total daily dose)
MTD
Dose: 7.5 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 7.5 mg/kg, 4 times / day
Sources: Page: p.527
unhealthy, 56
n = 7
Health Status: unhealthy
Condition: Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix
Age Group: 56
Sex: M+F
Population Size: 7
Sources: Page: p.527
PubMed

PubMed

TitleDatePubMed
Discovery, biochemistry and biology of lovastatin.
1988 Nov 11
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
1993 Nov 15
Effect of lipid-lowering strategies on tubular cell biology.
1999 Jul
Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
2000 May
Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma.
2001
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001 Apr
The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania mexicana.
2001 Apr 13
Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans.
2001 Apr 16
The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'.
2001 Aug
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
2001 Aug
[Endocrine disease in adrenoleukodystrophy].
2001 Feb
Butyrate-induced differentiation of Caco-2 cells occurs independently from p27.
2001 Feb 23
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
2001 Jan
Fragmentation study of simvastatin and lovastatin using electrospray ionization tandem mass spectrometry.
2001 Jan
Statin trials in progress: unanswered questions.
2001 Jan
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
2001 Jun
Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection.
2001 Jun
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.
2001 Jun
Use of statins and the subsequent development of deep vein thrombosis.
2001 Jun 11
Compactin enhances osteogenesis in murine embryonic stem cells.
2001 Jun 8
Recent advances in the biosynthetic studies of lovastatin.
2001 Mar
[Statins do not prevent restenosis after coronary angioplasty: where to go from here?].
2001 Mar
[AFCAPS/TexCAPS [The Air Force/Texas Coronary Atherosclerosis Prevention Study]].
2001 Mar
HMG-CoA reductase inhibitors and P-glycoprotein modulation.
2001 Mar
High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol.
2001 Mar 15
3-Hydroxy-3-methylglutaryl coenzyme A synthase-1 of Blattella germanica has structural and functional features of an active retrogene.
2001 Mar 15
The National Service Framework on coronary heart disease: is it sufficiently evidence-based?
2001 May
Statin induced myopathy does not show up in MIBI scintigraphy.
2001 May
Revised indications for statin therapies.
2001 May
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
2001 May
The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens.
2001 May
Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury.
2001 May
RhoA is activated during respiratory syncytial virus infection.
2001 May 10
Regulation of sterol regulatory element-binding proteins in hamster intestine by changes in cholesterol flux.
2001 May 18
Lovastatin controls signal transduction in vascular smooth muscle cells by modulating phosphorylation levels of mevalonate-independent pathways.
2001 May-Jun
Patents

Sample Use Guides

Hyperlipidemia and Mixed Dyslipidemia: (Fredrickson Types IIa and IIb). The recommended dosing range is 20-60 mg/day, in single doses taken in the evening at bedtime.
Route of Administration: Oral
Flow cytometry revealed significant increases in three of four lung cancer cell lines in apoptosis and necrosis after lovastatin treatment at 10 uM for 72 h. Lovastatin adversely affected lung cancer cell survival with increases in cell-cycle check-point inhibitors p21WAF and/or p27KIP and a decrease in cyclin D1. All four lung cancer cell lines had a decrease in glutathione after lovastatin treatment consistent with reduced protection against reactive oxidant species. Three of four lung cancer cell lines had increased cytochrome c release with reduced pro-caspase-3 and increases in activated caspase-3. Lovastatin induces apoptosis and necrosis in lung cancer cell lines by causing alterations in the cell cycle, reducing glutathione, and activating p53, Bax protein, and caspases while increasing cytochrome c in apoptosis pathways.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:06:12 GMT 2023
Edited
by admin
on Fri Dec 15 16:06:12 GMT 2023
Record UNII
5CLV35Y90C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LOVASTATIN ACID
Common Name English
LOVASTATIN IMPURITY B [EP IMPURITY]
Common Name English
MEVINOLINIC ACID
Common Name English
MSD-803 ACID
Code English
(.BETA.R,.DELTA.R,1S,2S,6R,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-.BETA.,.DELTA.-DIHYDROXY-2,6-DIMETHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-1-NAPHTHALENEHEPTANOIC ACID
Systematic Name English
MK-819
Code English
HYDROXYACID LOVASTATIN [EP IMPURITY]
Common Name English
1-NAPHTHALENEHEPTANOIC ACID, 1,2,6,7,8,8A-HEXAHYDRO-.BETA.,.DELTA.-DIHYDROXY-2,6-DIMETHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (.BETA.R,.DELTA.R,1S,2S,6R,8S,8AR)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1655
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
Code System Code Type Description
DRUG BANK
DB03785
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
FDA UNII
5CLV35Y90C
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
CAS
75225-51-3
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
PUBCHEM
64727
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID20873334
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
NCI_THESAURUS
C77442
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
CHEBI
82985
Created by admin on Fri Dec 15 16:06:12 GMT 2023 , Edited by admin on Fri Dec 15 16:06:12 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY